Belgian biotech Galapagos goes on a spending spree

22 June 2022

Belgian biotech company Galapagos (Euronext: GLPG) announced that it will acquire Dutch cell therapy company CellPoint and AboundBio to boost access to next-generation cell therapies, for around $250 million.

Galapagos chief executive Paul Stoffels said: “Our goal is to bring three differentiated, next-generation CAR-T candidates into the clinic over the next three years. This is a first key step in our strategic transformation to accelerate and diversify our pipeline with the aim to create short- and long-term value through focused external growth.”

Galapagos has lost more than 50% of its market value in the past year, as a result of a disappointing alliance with Gilead Sciences (Nasdaq: GILD), and the discontinuation of an important research candidate ziritaxestat (GLPG1690). Galapagos’ shares dipped 4% to 51.76 euros on the latest news.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK